<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650607</url>
  </required_header>
  <id_info>
    <org_study_id>en cours 3</org_study_id>
    <nct_id>NCT04650607</nct_id>
  </id_info>
  <brief_title>Phage Safety Cohort Study</brief_title>
  <acronym>PHA-SA-CO</acronym>
  <official_title>Phage Safety Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this cohort is to enhance knowledge of phage safety, whatever the purified phage&#xD;
      used in the next six years. Declaration of adverse reactions is required by EU data&#xD;
      protection rules, especially for off-label drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All potential serious adverse events in compassionate cases will be collected, and classified&#xD;
      as potentially related to surgery, to antibiotics, or to phages, with the help of the HCL&#xD;
      pharmacovigilance center. In addition, biobanking of pre- and post-treatment blood specimens&#xD;
      (serum and cells) will determine whether phage immunization is implicated in particular&#xD;
      adverse events. This observational cohort study will be initiated during year 1, in&#xD;
      compliance with all French health authority rules&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of adverse event</measure>
    <time_frame>12 months after the injection of phages</time_frame>
    <description>proportion of patient having an avderse event after injection of phages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>type of adverse event</measure>
    <time_frame>12 months after the injection of phages</time_frame>
    <description>description of the adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biobanking</measure>
    <time_frame>from before the injection of phages to 3 months after the surgery with injection of phages</time_frame>
    <description>to assess the role of immunization induced by phage phages in the occurrence of adverse</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <condition>Bone and Joint Infection</condition>
  <condition>Implant Infection</condition>
  <arm_group>
    <arm_group_label>Adverse event after injection of phages</arm_group_label>
    <description>patients having a BJI/PJI treated by injection of phages, with or without surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adverse event after injection of phages</intervention_name>
    <description>rate and description of adverse event after injection of phages</description>
    <arm_group_label>Adverse event after injection of phages</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients having a BJI/PJI treated by injection of phages at the time of the surgery managed&#xD;
        at the CRIOAC Lyon, Croix-Rousse Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients having a BJI/PJI treated by injection of phages at the time of the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eugenie Mabrut, CRA</last_name>
    <phone>04 26 73 29 38</phone>
    <email>eugenie.mabrut@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tristan Ferry, Md,PhD</last_name>
    <phone>04 26 73 29 38</phone>
    <email>tristan.ferry@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenie Mabrut, CRA</last_name>
      <phone>04 26 73 29 38</phone>
      <email>eugenie.mabrut@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.crioac-lyon.fr/</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phage</keyword>
  <keyword>adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

